%0 Journal Article %T Effects of Spironolactone on Cardiovascular Complications in Hemodialysis Patients of Taleghani Hospital During the Period of 2016-2017: A Randomized Double-Blind Controlled Clinical Trial %J Iranian Heart Journal %I Iranian Heart Association %Z %A Ziaee, Seyed Ahmad Reza %A Karvandi, Mersedeh %A Ziaee, Negar Sadat %A Gholizadeh Ghozloujeh, Zohre %A Shahrbaf, Mohammad Amin %A Roshan, Azamolsadat %D 2019 %\ 01/01/2019 %V 20 %N 1 %P 45-52 %! Effects of Spironolactone on Cardiovascular Complications in Hemodialysis Patients of Taleghani Hospital During the Period of 2016-2017: A Randomized Double-Blind Controlled Clinical Trial %K Chronic kidney disease %K echocardiography %K Left ventricular hypertrophy %K Spironolactone %K Ejection fraction %R %X Background: There is recent evidence that aldosterone plays a role in the pathogenesis ofcardiovascular diseases in dialysis patients, which leads to the opportunity to block its actionsfor the benefit of these patients. In non-dialytic chronic kidney diseases, spironolactone wassafe and effective in reducing left ventricular hypertrophy. However, its routine use has beenprecluded in hemodialysis patients due to the risk of hyperkalemia. The aim of the present studywas to verify the safety and efficacy of spironolactone in the regression of left ventricularhypertrophy and ejection fraction in hemodialysis patients undergoing pharmacotherapeuticmonitoring.Methods: We performed a controlled, randomized, double-blind study evaluating 48 hemodialysispatients divided into 2 groups. The first group received spironolactone at a dose of 25 mg afterhemodialysis over a few weeks, and the second group was the control. The patients werefollowed up for 9 months.Results: Both groups were composed of 24 patients each. The study groups did not differ in theirbaseline characteristics. The group receiving spironolactone had a significant improvement inthe left ventricular mass index and ejection fraction in comparison with the control group(P<0.05).Conclusions: Spironolactone treatment in hemodialysis patients was safe and effective in regressingleft ventricular hypertrophy and improving the ejection fraction as major risk factors forcardiovascular events in these patients. %U http://journal.iha.org.ir/article_82792_dafd20cddf1969fa5aa4e819dfba0637.pdf